Built For Regulated Life Sciences
Eight industries, one AI-first playbook for validation, compliance and clinical technology.
Cybroscape works across pharmaceuticals, biotechnology, medical devices, CROs, CDMOs and CRDMOs, cell and gene therapy, diagnostics, vaccines and healthcare technology. Each carries its own regulations, its own risk topology and its own decision-makers — but the standard for a defensible record is the same everywhere: traceable evidence, attributable decisions, and reasoning an inspector can follow.
What actually differs between industries
Three things, and they matter more than they first appear. The governing regulations differ — GMP with Annex 11 and Annex 15 for pharmaceutical manufacturing, MDR or IVDR and QSR for devices, GCP for clinical research. The risk topology differs: a sterile manufacturing line and a clinical database fail in entirely different ways and are inspected accordingly.
And the decision-makers differ. A pharma quality head, a device regulatory affairs lead and a CRO operations director are answering different questions and respond to different evidence. A vendor who speaks only one of those dialects gets a long way into the wrong conversation.
- The governing regulations
- The risk topology
- The decision-makers
What does not differ
The standard for a defensible record. Every test traces to a numbered requirement. Every deviation has a documented resolution rather than a note saying it was accepted. Every approval is attributable to a person who could realistically have checked what they signed. Records are tamper-evident, and that can be demonstrated rather than asserted.
Inspectors in every one of these industries pull on the same threads, because those threads are where the truth about an organisation's control is found.
- Every test traces to a requirement
- Every deviation has a documented outcome
- Every signature is attributable
- 01ResearchELNLIMSData that can support a filing
- 02ClinicalEDCeTMFCTMSTrial records and their audit trails
- 03ManufacturingMESERPSCADABatch records and process control
- 04QualityeQMSDocument managementDeviations, CAPA and change control
- 05Regulatory and safetyRIMSafety databaseSubmissions and safety cases
Company size changes the problem more than sector does
A Series B biotech and a top-twenty manufacturer deploying the same LIMS face the same Annex 11 and Part 11 expectations. What differs is everything around the obligation: a validation department, established templates, and a QA function that has done this fifty times — none of which the smaller company has.
In practice that gap drives more of how an engagement should be scoped than the industry label does. The economics are set out in mid-market validation economics.
Illustrative.
Assets, not just applications
Industries differ sharply in what they actually need qualified. A diagnostics laboratory is concerned with analytical instruments under USP <1058>. A sterile manufacturer is concerned with equipment under EU GMP Annex 15. A clinical research organisation is concerned with software under GAMP 5 and with clinical documents.
Forcing instruments and equipment through a software validation lifecycle produces documents that do not match what a qualification auditor expects to see — which is why the right track matters as much as the right rigour.
LIMS, MES, ERP, eQMS, RIM
Analytical and lab instruments
Process equipment and utilities
Models, agents and copilots
Common questions
Prefer to talk first? Chat with us on WhatsApp or book a call with an expert.
Which industries does Cybroscape serve?
Pharmaceuticals, biotechnology, medical devices, contract research organisations, diagnostics, vaccines, healthcare technology including SaMD and digital health, and life sciences more broadly. The common thread is a regulated process where a computerised system or a clinical document has to withstand inspection.
Does validation differ between pharma and medical devices?
The lifecycle is similar; the governing regulations and the evidence a reviewer expects are not. Pharmaceutical manufacturing answers to GMP, Annex 11 and Annex 15. Medical devices answer to MDR or IVDR and QSR, with clinical evaluation and post-market surveillance obligations that have no direct pharma equivalent.
What is different about validation for a CRO?
The constraint is usually throughput rather than compliance posture. CROs run many studies across many sponsors, each with its own templates and expectations, so the pressure falls on clinical writing capacity and on demonstrating consistency across sponsors — rather than on validating a small number of manufacturing systems deeply.
Do small biotechs really need full validation?
They need validation proportionate to risk, which is not the same as a large manufacturer's package. A Series B biotech faces the same regulatory obligation without a validation department, so the answer is usually correct categorisation, leveraged supplier evidence and a lean but complete lifecycle — not a scaled-down copy of a big pharma template.
What stays the same across every industry?
That evidence must be traceable, decisions must be attributable to a person, records must be tamper-evident, and an inspector must be able to follow the reasoning. The regulations differ, the risk topology differs, the decision-makers differ — what a defensible record looks like does not.
Talk to someone who knows your industry.
Our leads have shipped inspection-ready systems in FDA, EMA, MHRA, PMDA and CDSCO environments.
- We reply within one business day
- We run your URS live on the call
- You get a clear plan for your system